Trxade Group (TRXD) Rating Increased to Buy at Zacks Investment Research
Trxade Group (OTCMKTS:TRXD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday. The brokerage currently has a $0.25 target price on the stock. Zacks Investment Research‘s price objective would indicate a potential downside of 28.82% from the company’s current price.
According to Zacks, “Trxade Group, Inc. is a web based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories and services. The company’s products and services include Web-based pharmaceutical marketplaces comprising Trxade.com and Trxade.com; Pharmabayonline, which offers access to proprietary pharmaceutical data analytics to the United States-based independent pharmacies; RxGuru, a software as a service-based desktop application that provides daily drug pricing and analytics to the independent pharmacists; and Pinnacle Tek, an information technology consulting and staffing solution. Trxade Group, Inc. is based in Lutz, Florida. “
Separately, Taglich Brothers restated a “speculative buy” rating on shares of Trxade Group in a report on Friday, October 6th.
About Trxade Group
Trxade Group, Inc (Trxade) designs, develops, owns and operates a business-to-business Web-based marketplace focused on the United States pharmaceutical industry. The Company’s products and services include Trxade.com, InventoryRx.com, Pharmabayonline and RxGuru. Its services are distributed through its online platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trxade Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trxade Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.